A Potential Link between Myeloperoxidase Modified LDL, Atherosclerosis and Depression.

Area of Science:

• Cardiovascular Biology
• Neuroscience
• Pathophysiology

Background:

• Atherosclerosis involves modified low-density lipoproteins (LDL), with myeloperoxidase oxidized LDL (Mox-LDL) being highly pathogenic and present in plaques.
• Mox-LDL is implicated in sleep disorders, heart disease, and depression.
• Recent findings show lox-1-mediated Mox-LDL signaling affects neuroserpin activity in endothelial cells, impacting cerebrovascular disease (CD).

Purpose of the Study:

• To explore the link between Mox-LDL, tissue plasminogen activator (tPA), and brain-derived neurotrophic factor (BDNF) in the context of major depressive disorder (MDD).
• To investigate the potential role of Mox-LDL-driven changes in tPA activity on BDNF maturation and its implications for neural plasticity and depression.

Main Methods:

• The study speculates on the mechanistic link based on existing literature and recent findings on Mox-LDL signaling.
• Analysis of the interaction between Mox-LDL, neuroserpin, tPA, and BDNF pathways.

Main Results:

• Mox-LDL signaling modulates neuroserpin activity, affecting tPA, a key enzyme in BDNF maturation.
• A potential pathway suggests Mox-LDL may decrease mature BDNF by altering tPA activity, impacting neural plasticity.
• This mechanism could link atherosclerosis to depression.

Conclusions:

• Deciphering the interaction between Mox-LDL, tPA, and BDNF offers insights into overlapping pathologies in CD and MDD.
• This understanding may reveal novel, common therapeutic strategies for cardiovascular and depressive disorders.